QPPV.COM KNOWLEDGE ASSESSMENT

Zanidatamab: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Zanidatamab: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is the report date relevant when assessing expectedness?
Question 2 of 10 In a patient who develops diarrhoea after zanidatamab, why should the assessment include obstruction, cholangitis, infection and recent antibiotics?
Question 3 of 10 What conclusion can spontaneous reports most appropriately support in relation to zanidatamab safety?
Question 4 of 10 Which set of data would best support traceability of whether treatment matched the authorised population?
Question 5 of 10 A report describes a patient as having 'HER2-positive biliary cancer' but gives no immunohistochemistry score. What is the most appropriate pharmacovigilance action?
Question 6 of 10 Which feature most specifically distinguishes zanidatamab's antibody design from a conventional single-epitope HER2-directed antibody?
Question 7 of 10 Before counting cases of serious diarrhoea in an aggregate review, what should the safety team do first?
Question 8 of 10 Why should a pharmacovigilance record preserve the exact HER2-directed active substance rather than recording only that the patient received a HER2 therapy?
Question 9 of 10 A patient develops fever, hypotension and dyspnoea during an infusion. Which approach is most appropriate?
Question 10 of 10 Which information best characterizes the clinical severity of diarrhoea in an individual case?

Select an answer to continue.

QPPV.com